07:00 , May 28, 2012 |  BC Week In Review  |  Clinical News

BST-CarGel: Phase III data

An international, blinded Phase III trial in 80 patients aged 18-55 with single symptomatic grade III/IV focal lesions on femoral condyles showed that BST-CarGel met the co-primary endpoints of greater lesion filling and superior repair...
07:00 , Apr 5, 2010 |  BioCentury  |  Finance

2Q Financial Markets Preview: Wanted Dry Powder

Biotech run-ups have historically cooled after 25-30% gains. Thus the question going into the second quarter is whether there's momentum to keep going, or whether the sector will take a breather. The historical numbers are...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

BST-CarGel: Pivotal trial interim data

Interim data from an ongoing, Canadian and European pivotal trial in 22 evaluable patients showed that BST-CarGel treatment of microfractures significantly improved overall International Cartilage Repair Society II scores compared with untreated microfractures (64.5 vs....
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

BST-CarGel: Completed pivotal trial enrollment

BioSyntech completed enrollment of 80 patients with acute or chronic focal cartilage lesions of the knee in a Canadian and European pivotal trial evaluating microfacture with and without BST-CarGel. BioSyntech Inc. (TSX:BSY), Laval, Quebec  ...
08:00 , Mar 6, 2006 |  BC Week In Review  |  Clinical News

BST-CarGel: Phase III started

BSY started a Canadian Phase III trial in up to 80 patients. BioSyntech Inc. (TSX-V:BSY), Laval, Quebec   Product: BST-CarGel   Business: Musculoskeletal   Molecular target: Not applicable   Description: BST-Gel hydrogel mixed with the...
08:00 , Feb 20, 2006 |  BC Week In Review  |  Company News

BioSyntech, Kuhnil Pharma Co. Ltd. deal

BSY granted Kuhnil exclusive Korean marketing and distribution rights to BST-CarGel to repair localized cartilage regions and BST-InPod to treat chronic heal pain. Kuhnil purchased 1.5 million BSY shares at C$0.80. BST-CarGel is in Phase...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Clinical News

BioSyntech preclinical data

BSY published in The Journal of Bone and Joint Surgery that, in sheep with damaged cartilage in the knees, BST-CarGel led to significantly more hyaline repair tissue compared with untreated controls at 6 months (p<0.05)....